SynAct Pharma AB (SYNACT) — Cash Flow-to-Debt Ratio
Latest as of March 2026:
-0.75x
SynAct Pharma AB (SYNACT) has a Cash Flow-to-Debt Ratio of -0.75x as of March 2026, meaning its operating cash flow of Skr-32.95 Million could theoretically repay -1% of its total liabilities (Skr44.13 Million) in one year. See SynAct Pharma AB leverage flexibility ratio to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
-0.75x
Operating CF / Total Liabilities
Operating Cash Flow
Skr-32.95 Million
SEK
Total Liabilities
Skr44.13 Million
SEK
Data as of
Mar 2026
Most recent filing
SynAct Pharma AB Cash Flow-to-Debt Ratio (2016–2025)
Historical debt coverage capacity for SynAct Pharma AB across 10 annual periods. For the full cash flow conversion analysis, see how efficiently does SynAct Pharma AB generate cash.
Annual Cash Flow-to-Debt Ratio for SynAct Pharma AB (2016–2025)
Year-by-year debt coverage analysis for SynAct Pharma AB.
| Year | CF-to-Debt Ratio | Operating CF (SEK) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -1.94x | Skr-97.33 Million | Skr50.23 Million | ▼ -22.4% |
| 2024 | -1.58x | Skr-89.20 Million | Skr56.35 Million | ▲ +18.1% |
| 2023 | -1.93x | Skr-100.18 Million | Skr51.83 Million | ▲ +73.6% |
| 2022 | -7.31x | Skr-117.56 Million | Skr16.08 Million | ▼ -96.9% |
| 2021 | -3.71x | Skr-65.00 Million | Skr17.50 Million | ▲ +36.0% |
| 2020 | -5.81x | Skr-33.24 Million | Skr5.72 Million | ▼ -271.3% |
| 2019 | -1.56x | Skr-16.12 Million | Skr10.31 Million | ▲ +76.0% |
| 2018 | -6.52x | Skr-24.21 Million | Skr3.72 Million | ▲ +12.4% |
| 2017 | -7.44x | Skr-17.20 Million | Skr2.31 Million | ▼ -76.3% |
| 2016 | -4.22x | Skr-14.73 Million | Skr3.49 Million | — |
Cash Flow-to-Debt Ratio = Operating Cash Flow / Total Liabilities. Higher is better for debt service capacity.